Market capitalization | $720.88m |
Enterprise Value | $2.07b |
PER (TTM) P/E ratio | 10.27 |
EV/FCF (TTM) EV/FCF | 220.22 |
EV/Sales (TTM) EV/Sales | 1.83 |
P/S ratio (TTM) P/S ratio | 0.64 |
P/B ratio (TTM) P/B ratio | negative |
Dividend yield | 4.80% |
Last dividend (FY23) | $0.60 |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
4 Analysts have issued a Embecta forecast:
4 Analysts have issued a Embecta forecast:
Mar '24 |
+/-
%
|
||
Turnover | 1,133 1,133 |
1%
1%
|
|
Gross income | 741 741 |
2%
2%
|
|
EBITDA | 265 265 |
21%
21%
|
EBIT (operating result) EBIT | 228 228 |
25%
25%
|
Net profit | 70 70 |
26%
26%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
Head office | United States |
CEO | Devdatt Kurdikar |
Employees | 2,200 |
Founded | 1924 |
Website | www.embecta.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.